We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| GW Pharm. | LSE:GWP | London | Ordinary Share | GB0030544687 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 735.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Jun 2019 to Jun 2024
TIDMGWP
RNS Number : 8355P
GW Pharmaceuticals PLC
22 November 2016
GW Pharmaceuticals to Present at the 28(th) Annual Piper Jaffray Healthcare Conference on 29 November
London, UK, 22 November 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW's Chief Executive Officer, will present at the 28(th) Annual Piper Jaffray Healthcare Conference on Tuesday, 29 November 2016, at 10:30 a.m. ET at the Lotte New York Palace, New York City.
A live audio webcast of the presentation will be available through GW's corporate website in the investor relations section from the investor's calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentation.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex(R) (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex(R), which is approved for the treatment of spasticity due to multiple sclerosis in 30 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc Stephen Schultz, VP Investor 917 280 2424 / 401 500 Relations (U.S.) 6570 Peel Hunt LLP (UK NOMAD) James Steel +44 20 7418 8900
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCKMMZMMZZGVZM
(END) Dow Jones Newswires
November 22, 2016 08:00 ET (13:00 GMT)
1 Year Gw Pharmaceuticals Chart |
1 Month Gw Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
